CEE-03-310 CeNeS pharmaceuticals.
CEE-03-310 is a selective dopamine D1-like receptor antagonist with no appreciable binding affinity for other receptors. Although originally developed by Novo Nordisk A/S as NNC-687 for the treatment of schizophrenia, the company changed its therapeutic focus in the mid-1990s and the full rights to CEE-03-310 and several related compounds were subsequently granted to CeNeS Pharmaceuticals in 1999. CeNeS is currently investigating the drug's potential in the treatment of insomnia and alcohol dependency [340965], [382293], [401496],[416026]. A phase II, double-blind, placebo-controlled trial of CEE-03-310 demonstrated a dose-dependent enhancement of NREM sleep at the beginning of the night without any effects on the quantity of REM sleep [410739].
Eder
Derek N
DN
Gothenburg University, Institute of Clinical Neuroscience, Section for Psychiatry, Sahlgrenska Hospital, SU/SS, Göteborg, Sweden. derek.eder@neuroscience.gu.se
D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001572:Benzofurans / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018492:Dopamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007928:Lethal Dose 50; D016032:Randomized Controlled Trials as Topic; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D001552:Benzazepines; D001572:Benzofurans; D018492:Dopamine Antagonists; D015507:Drugs, Investigational; D017447:Receptors, Dopamine D1; C077122:5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol